Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Leighl's Highlights in Lung Cancer from 2012: MEK Inhibitor Therapy for KRAS Mutation-Positive NSCLC
Author
Howard (Jack) West, MD

Pre and post MEKiThe next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation. KRAS is the most common mutation seen in lung cancer, found in about 20-25% of patients with NSCLC, in different histologies and with different smoking histories, but we haven't had an effective therapy for this group of patients, in whom some evidence suggests that both EGFR inhibitors and standard chemotherapy are less effective.

Dr. Leighl's podcast discusses encouraging work that suggests a potential value in adding a MEK inhibitor to standard chemo, though ensuring that it's a tolerable combination is something we'll need to continue to work on (in addition to confirming the activity of MEK inhibitors in larger trials).  Here's her presentation in video and audio format, as well as the figures for it.

[powerpress]

Dr. Leighl Highlights in LC 2012 Pt 3 MEK for KRAS Mutn Audio Podcast

Dr. Leighl Highlights in LC 2012 Pt 3 MEK for KRAS Mutn Figs

Dr. Leighl's Highlights in Lung Cancer, 2012 program next turned to squamous cell carcinoma and anti-PD1 immunotherapy work, so look for that here very soon.  In the meantime, I hope you find this program helpful and promising!

 

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on